ShareValue scores for R1DY34.SA: Valuation 49, Quality 30, Growth 36, Health 46.

R1DY34.SA
B3

Dr. Reddy's Laboratories Limited

R$12.10(0.00%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

5% to 16%
Valuation
49
Fair Value
Price vs Value
Quality
30
Weak
Business Strength
Growth
36
Weak
Revenue & Earnings
Health
46
Moderate
Financial Stability
Momentum
44
Neutral
Price Trend

Company Details

About

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026